OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Mamounas on the Role of Extended Adjuvant Endocrine Therapy in ER+ Breast Cancer

August 24th 2020

Eleftherios (Terry) P. Mamounas, MD, MPH, FACS, discusses the role of extended adjuvant endocrine receptor–positive breast cancer.

Dr. Saba on Scheduling Challenges With Cisplatin in Head and Neck Cancer

August 24th 2020

Nabil F. Saba, MD, FACP, discusses scheduling challenges with cisplatin in head and neck cancer.

Dr. Chang on the Impact of COVID-19 on the Surgical Management of GU Cancers

August 24th 2020

Steven Lee Chang, MD, discusses the impact of the coronavirus disease 2019 on the surgical management of patients with genitourinary cancers.

Dr. Leslie on Phase 1b Trial of Tazemetostat Plus Lenalidomide/Rituximab in Follicular Lymphoma

August 22nd 2020

Lori A. Leslie, MD, discusses a phase 1b study with tazemetostat plus lenalidomide and rituximab in patients with follicular lymphoma.

Dr. Skarbnik on Active Surveillance in Follicular Lymphoma

August 22nd 2020

Alan P. Z. Skarbnik, MD, discusses the watch-and-wait approach in patients with follicular lymphoma.

Dr. Burke on Tazemetostat’s Mechanism of Action in EZH2-Mutated Follicular Lymphoma

August 22nd 2020

John M. Burke, MD, discusses the role of tazemetostat in EZH2-mutated follicular lymphoma.

Dr. Reid on Remaining Challenges Regarding the Management of Immune-Related AEs

August 21st 2020

Pankti Reid, MD, MPH, discusses remaining challenges regarding the management of immune-related adverse effects.

Dr. Garon on Unique Challenges of COVID-19 in Lung Cancer

August 21st 2020

Edward B. Garon, MD, discusses unique challenges of the coronavirus disease 2019 in lung cancer.

Dr. Garon on the Expanding Treatment Landscape in Lung Cancer

August 21st 2020

Edward B. Garon, MD, discusses the expanding treatment landscape in lung cancer.

Dr. Chu on the Impact of the KEYNOTE-177 Trial in mCRC

August 21st 2020

Edward Chu, MD, MMS, discusses the impact of the phase 3 MK-3475-177/KEYNOTE-177 trial in metastatic colorectal cancer.

Dr. Burris on the Utility of Sacituzumab Govitecan in Metastatic TNBC

August 21st 2020

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses the utility of sacituzumab govitecan-hziy in metastatic triple-negative breast cancer.

Dr. Abraham on Future Research in TGCT

August 21st 2020

John A. Abraham, MD, FACS, discusses future research efforts in tenosynovial giant cell tumor.

Dr. Chari on Investigational Belantamab Mafodotin Combos in Myeloma

August 20th 2020

Ajai Chari, MD, discusses next steps with belantamab mafodotin-blmf and combination studies in multiple myeloma.

Dr. Reardon on a Phase 1/2 Trial Examining INO-5401 and INO-9012 in Glioblastoma

August 20th 2020

David A. Reardon, MD, discusses the design of a phase 1/2 trial with INO-5401 and INO-9012 in glioblastoma.

Dr. Richard on Treatment According to Transplant Eligibility in Multiple Myeloma

August 20th 2020

Shambavi Richard, MD, discusses treatment according to transplant eligibility in multiple myeloma.

Dr. Somaiah on Remaining Challenges in Soft Tissue Sarcoma

August 20th 2020

Neeta Somaiah, MD, discusses remaining challenges in soft tissue sarcoma.

Dr. Johnson on the Limitations of Biomarkers in Melanoma

August 20th 2020

Douglas B. Johnson, MD, MSCI, discusses the limitations of biomarkers in melanoma.

Dr. Harrington on the KEYNOTE-048 Trial in Recurrent/Metastatic Head and Neck Cancer

August 20th 2020

Kevin Harrington, BSc, MBBS, PhD, MRCP, FRCP, FRCR, discusses the randomized phase 3 KEYNOTE-048 trial in recurrent/metastatic head and neck squamous cell carcinoma.

Dr. Ravi on the Evolving Treatment Landscape of Advanced Bladder Cancer

August 20th 2020

Praful K. Ravi, MD, discusses the evolving treatment landscape of advanced bladder cancer.

Dr. Jonasch on the Role of Inhibiting HIF-2α in Von Hippel-Lindau Disease–Associated RCC

August 20th 2020

Eric Jonasch, MD, discusses the role of inhibiting hypoxia-inducible factor-2α in Von Hippel-Lindau disease–associated renal cell carcinoma.